These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26209679)

  • 1. Inhibition of HIV-1 gp41 expression with hammerhead ribozymes.
    Fedoruk-Wyszomirska A; Szymański M; Głodowicz P; Gabryelska M; Wyszko E; Estrin WJ; Barciszewski J
    Biochem J; 2015 Oct; 471(1):53-66. PubMed ID: 26209679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly active low magnesium hammerhead ribozyme.
    Fedoruk-Wyszomirska A; Szymański M; Wyszko E; Barciszewska MZ; Barciszewski J
    J Biochem; 2009 Apr; 145(4):451-9. PubMed ID: 19124457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.
    Bramlage B; Luzi E; Eckstein F
    Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravirion targeting of a functional anti-human immunodeficiency virus ribozyme directed to pol.
    Giordano V; Jin DY; Rekosh D; Jeang KT
    Virology; 2000 Feb; 267(2):174-84. PubMed ID: 10662613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry.
    Zhang X; Iwatani Y; Shimayama T; Yamada R; Koito A; Xu Y; Sakai H; Uchiyama T; Hattori T
    Antisense Nucleic Acid Drug Dev; 1998 Dec; 8(6):441-50. PubMed ID: 9918108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme.
    Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC
    Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
    Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
    Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribozyme targeting of HIV-1 LTR.
    Ventura M; Wang P; Franck N; Saragosti S
    Biochem Biophys Res Commun; 1994 Sep; 203(2):889-98. PubMed ID: 8093072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of the highly conserved hairpin-loop region of HIV-1 by synthetic ribozymes.
    Shimayama T; Nishikawa S; Taira K
    Nucleic Acids Symp Ser; 1993; (29):177-8. PubMed ID: 8247758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1.
    Unwalla HJ; Li H; Li SY; Abad D; Rossi JJ
    Mol Ther; 2008 Jun; 16(6):1113-9. PubMed ID: 18388915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
    Akkina R; Banerjea A; Bai J; Anderson J; Li MJ; Rossi J
    Anticancer Res; 2003; 23(3A):1997-2005. PubMed ID: 12894572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribozymes in gene therapy of HIV-1.
    Macpherson JL; Ely JA; Sun LQ; Symonds GP
    Front Biosci; 1999 Jun; 4():D497-505. PubMed ID: 10352136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation.
    Pröpsting MJ; Blaschke M; Haas RE; Genschel J; Hedrich HJ; Manns MP; Schmidt HH
    Biochem Biophys Res Commun; 1999 Jul; 260(2):313-7. PubMed ID: 10403767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1.
    Ramezani A; Ma XZ; Nazari R; Joshi S
    Front Biosci; 2002 Feb; 7():a29-36. PubMed ID: 11815297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
    Ramezani A; Ding SF; Joshi S
    Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.